Amorphous Solid Dispersion of a Binary Formulation with Felodipine and HPMC for 3D Printed Floating Tablets

This study focuses on the combination of three-dimensional printing (3DP) and amorphous solid dispersion (ASD) technologies for the manufacturing of gastroretentive floating tablets. Employing hot melt extrusion (HME) and fused deposition modeling (FDM), the study investigates the development of dru...

Descripción completa

Detalles Bibliográficos
Autores: Mora Castaño, Gloria, Millán Jiménez, Mónica, Niederquell, Andreas, Schonenberger, Monica, Shojaie, Fatemeh, Kuentz, Martin, Caraballo Rodríguez, Isidoro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/165146
Acceso en línea:https://hdl.handle.net/11441/165146
https://doi.org/10.1016/j.ijpharm.2024.124215
Access Level:acceso abierto
Palabra clave:3D printing
Amorphous solid dispersion
Drug-loaded filaments
Fused deposition modeling
Gastroretentive floating tablets
Zero-order release
Descripción
Sumario:This study focuses on the combination of three-dimensional printing (3DP) and amorphous solid dispersion (ASD) technologies for the manufacturing of gastroretentive floating tablets. Employing hot melt extrusion (HME) and fused deposition modeling (FDM), the study investigates the development of drug-loaded filaments and 3D printed (3DP) tablets containing felodipine as model drug and hydroxypropyl methylcellulose (HPMC) as the polymeric carrier. Prior to fabrication, solubility parameter estimation and molecular dynamics simulations were applied to predict drug-polymer interactions, which are crucial for ASD formation. Physical bulk and surface characterization complemented the quality control of both drug-loaded filaments and 3DP tablets. The analysis confirmed a successful amorphous dispersion of felodipine within the polymeric matrix. Furthermore, the low infill percentage and enclosed design of the 3DP tablet allowed for obtaining low-density systems. This structure resulted in buoyancy during the entire drug release process until a complete dissolution of the 3DP tablets (more than 8 h) was attained. The particular design made it possible for a single polymer to achieve a zero-order controlled release of the drug, which is considered the ideal kinetics for a gastroretentive system. Accordingly, this study can be seen as an advancement in ASD formulation for 3DP technology within pharmaceutics.